Sjögren’s Syndrome News

Nicox today announced the US launch of an advanced diagnostic test for the earlier detection of Sjögren’s syndrome.

OphthaliX recently announced that its parent company, Can-Fite BioPharma, has been granted a patent by the European Patent Office for its drug candidate CF101 for treatment of Sjögren’s syndrome in Europe until 2025.

Determining cut-off levels of beta2-microglobulin and sodium markers in saliva effectively differentiated Sjögren’s syndrome patients from non-Sjögren’s syndrome patients and healthy controls in a recent study.

Nicox has entered into an exclusive agreement with Immco Diagnostics to help promote Immco’s proprietary laboratory test for early detection and diagnosis of Sjögren’s syndrome, according to a press release.

Four novel autoantibody biomarkers could significantly improve diagnoses of rheumatoid arthritis, according to research presented at the annual congress of the European League Against Rheumatism in Madrid.

Almost one-fifth of patients with systemic lupus erythematosus developed Sjögren’s syndrome, which presented itself early in the disease progression, according to study results.

Aggressive early therapy with pulse corticosteroids and cyclophosphamide in patients presenting with neurosjögren resulted in successful recoveries in a recent study.

Patients with systemic lupus erythematosus who took immunosuppressive medications did not necessarily increase their risk for lymphoma, and those exposed to cyclophosphamide had only a relatively low rate of incidence, according to study results.

Patients with systemic lupus erythematosus who took immunosuppressive medications did not necessarily increase their risk for lymphoma, and those exposed to cyclophosphamide had only a relatively low rate of incidence, according to study results.

Fibromyalgia appeared to contribute to symptoms more in patients with systemic lupus erythematosus than in patients with primary Sjögren’s syndrome, according to study results.